IGF-1 LR3 vs GH secretagogues
IGF-1 LR3 vs GH secretagogues — direct vs upstream pathway, IGF-1 elevation magnitude, side effects, cycle length, and a practical decision framework.
Updated May 7, 2026 · 5 min read
IGF-1 LR3 and GH secretagogues sit at opposite ends of the same axis. Secretagogues like Sermorelin, Ipamorelin, and CJC-1295 trigger your pituitary to release more growth hormone, which then signals the liver to produce IGF-1. IGF-1 LR3 skips the whole upstream chain and injects the endpoint molecule directly. The decision between them is mostly about how aggressive you want to be, what side-effect profile you can tolerate, and whether you need the broader recovery and sleep benefits secretagogues bring.
The pathway difference
| Pathway step | GH secretagogues | IGF-1 LR3 |
|---|---|---|
| Hypothalamus | Active | Bypassed |
| Pituitary GH release | Triggered | Suppressed via feedback |
| Liver IGF-1 production | Stimulated | Suppressed via feedback |
| IGF-1 receptor activation | Modest, pulsatile | Strong, sustained |
| Endogenous regulation | Intact | Bypassed |
Secretagogues amplify your natural GH/IGF-1 rhythm. IGF-1 LR3 overrides it. That difference shows up in nearly every property that matters.
Magnitude of IGF-1 elevation
| Protocol | IGF-1 elevation (rough) |
|---|---|
| Sermorelin alone, standard dose | 20–40% above baseline |
| Ipamorelin + CJC-1295 (no DAC) | 30–60% above baseline |
| CJC-1295 with DAC, high dose | 60–100% above baseline |
| MK-677, standard dose | 40–80% above baseline |
| IGF-1 LR3, 40 mcg/day | Substantially above baseline, sustained |
| IGF-1 LR3, 60–80 mcg/day | Markedly supraphysiologic |
These numbers vary widely by individual; treat them as relative magnitudes, not absolute targets.
The practical implication: secretagogues nudge you into the high end of your physiologic IGF-1 range. IGF-1 LR3 takes you above it.
Side-effect intensity
| Effect | Secretagogues | IGF-1 LR3 |
|---|---|---|
| Hypoglycemia | Mild, uncommon | Common, dose-dependent |
| Hand numbness / carpal tunnel | Occasional, mild | Occasional, sharper |
| Water retention | Mild | Mild |
| Headaches | Rare | Occasional |
| Joint aches | Mild, transient | Occasional |
| Fatigue | Mild week 1 | Common week 1 |
| Sleep changes | Often improved (vivid dreams) | Variable |
Secretagogues are the gentler tool. IGF-1 LR3 has more acute tolerability questions.
Cycle length
- Secretagogues: 12–16 weeks typical. The GH/IGF-1 effect builds slowly, so short cycles miss the body-comp signal.
- IGF-1 LR3: 4–6 weeks typical. Longer cycles run into receptor desensitization and amplified cancer-axis exposure.
This matters more than people realize. Secretagogues are a long-game tool. IGF-1 LR3 is a short, focused block.
Cost per cycle
| Protocol | Approximate cost |
|---|---|
| Sermorelin alone (12 wk) | $200–400 |
| Ipa + CJC no-DAC (12 wk) | $300–600 |
| MK-677 oral (12 wk) | $150–300 |
| Tesamorelin (12 wk) | $600–1,200 |
| IGF-1 LR3 alone (5 wk) | $200–400 |
| IGF-1 LR3 + Ipa/CJC stack (5 wk) | $400–700 |
On a per-week basis IGF-1 LR3 is more expensive, but the shorter cycle keeps total cost in a similar band to secretagogue cycles.
What each tool does well
Secretagogues are best for:
- Sleep quality and recovery improvements that build over weeks
- Sustained body-comp shifts on a long cycle
- Users new to the GH/IGF-1 axis
- Lower-risk profile relative to direct IGF-1 elevation
- Preserving endogenous regulation
IGF-1 LR3 is best for:
- Short, focused anabolic blocks (4–6 weeks)
- Experienced users who have already run secretagogues and want more
- Specific body-comp goals where IGF-1 elevation is the lever
- Users willing to accept a sharper risk profile for stronger acute signal
When secretagogues are enough
Most strength-community users get most of what they want from secretagogues. If your goals are:
- Better sleep
- Faster recovery between sessions
- Slow body-comp drift
- Sustained, low-risk GH/IGF-1 axis support
You don't need IGF-1 LR3. The Ipa+CJC stack run for 12–16 weeks delivers the relevant signal at a lower-risk profile.
When IGF-1 LR3 makes sense
Cases where stepping up to IGF-1 LR3 is defensible:
- Ran a full secretagogue cycle and want stronger anabolic signaling
- Specific 4–6 week block where maximum tissue-building support is the goal
- Tolerated secretagogue side effects cleanly and labs looked good
- No personal or family cancer history that would contraindicate IGF-1 elevation
- Willing to set up baseline labs and end-of-cycle monitoring
A practical decision tree
- Never run any GH/IGF-1 axis peptide? → Start with Sermorelin or Ipa+CJC. Don't open with IGF-1 LR3.
- Goal is recovery and sleep? → Secretagogues, full cycle.
- Goal is slow body-comp shift over months? → Secretagogues.
- Want a short focused anabolic block, with prior secretagogue experience? → IGF-1 LR3, 4–6 weeks.
- Want both sustained GH-axis activity and stronger IGF-1 signal? → Stack them. See stacking IGF-1 LR3 with GH peptides.
- Active or recent cancer, or strong family history of hormone-sensitive cancer? → Neither. See cancer concerns.
The honest framing
For most users, the secretagogue category is the right tool. It produces a meaningful fraction of what people want from the GH/IGF-1 axis with a milder risk profile. IGF-1 LR3 is a real tool with real benefits for the right user, but it's not a default starting point and it's not a long-term strategy. If you've never run GH peptides, start with secretagogues. If you've run secretagogues and want more, then IGF-1 LR3 enters the conversation.